Andra AP fonden Sells 15,000 Shares of AbbVie Inc. $ABBV

Posted by Brian Himes on Sep 22nd, 2026

Andra AP fonden decreased its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 5.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 268,811 shares of the company’s stock after selling 15,000 shares during the period. AbbVie comprises about 0.7% of Andra AP fonden’s investment portfolio, making the stock its 23rd biggest holding. Andra AP fonden’s holdings in AbbVie were worth $67,644,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. ACT Advisors LLC. raised its holdings in shares of AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after purchasing an additional 41 shares during the last quarter. Willner & Heller LLC raised its stake in AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock valued at $1,472,000 after buying an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC boosted its stake in shares of AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after buying an additional 43 shares during the last quarter. Fielder Capital Group LLC boosted its stake in shares of AbbVie by 1.7% in the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after buying an additional 43 shares during the last quarter. Finally, Guardian Wealth Advisors LLC NC grew its holdings in shares of AbbVie by 0.4% in the second quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock worth $2,996,000 after acquiring an additional 43 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE:ABBV traded up $1.03 on Tuesday, reaching $265.51. The company’s stock had a trading volume of 892,624 shares, compared to its average volume of 6,538,061. The company has a 50-day simple moving average of $255.90 and a 200 day simple moving average of $232.37. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The company has a market cap of $469.10 billion, a P/E ratio of 75.07, a PEG ratio of 1.19 and a beta of 0.29.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is 195.48%.

Insider Activity at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: RINVOQ gains another European indication. The European Commission approved RINVOQ (upadacitinib) for children aged two and older with active polyarticular juvenile idiopathic arthritis who have not responded adequately to, or cannot tolerate, one or more DMARDs. The approval expands RINVOQ’s commercial reach and adds to its 11 approved EU indications, reinforcing the drug as a key growth driver for AbbVie. AbbVie Announces European Commission Approval of RINVOQ
Positive Sentiment: AbbVie expands its AI drug-discovery strategy. AbbVie entered a multiyear collaboration with Iambic to use the company’s AI platform to identify and develop small-molecule therapies in immunology, neuroscience and oncology. The partnership could improve discovery efficiency and diversify AbbVie’s long-term pipeline, although any financial benefits are likely to take years to materialize. AbbVie and Iambic Announce Collaboration
Positive Sentiment: Allergan Aesthetics launched AA Signature: SKIN360 in the U.S. The multimodal consultation program is intended to help providers address patients’ broader aesthetic goals and could support engagement across AbbVie’s aesthetics portfolio. The near-term earnings impact is not specified. Allergan Aesthetics Debuts AA Signature
Neutral Sentiment: Recent commentary continues to highlight AbbVie’s dividend appeal and second-quarter results, which exceeded analyst expectations for both earnings and revenue. These reports support the stock’s defensive investment case, but largely reiterate previously reported information rather than provide a new catalyst. AbbVie vs. Pfizer

Analyst Ratings Changes

Several research analysts have issued reports on ABBV shares. Bank of America reissued a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target on the stock in a report on Thursday, August 13th. HSBC raised their target price on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Finally, Piper Sandler increased their price objective on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $276.64.

Check Out Our Latest Report on ABBV

About AbbVie

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.